Related Experiment Videos
Abnormal pro-opiomelanocortin processing in Alzheimer's disease. A case report
F Facchinetti1, A R Storchi, C Pacchetti
1Department of Obstetrics and Gynecology, University of Modena, Italy.
Functional Neurology
|July 1, 1987
Summary
Reduced pro-opiomelanocortin (POMC) peptides in Alzheimer's disease (AD) cerebrospinal fluid may stem from transport or secretion issues, not synthesis defects. This case study investigated POMC processing post-mortem in an AD patient versus a control.
Area of Science:
- Neuroscience
- Endocrinology
- Biochemistry
Background:
- Reduced pro-opiomelanocortin (POMC)-related peptides in cerebrospinal fluid (CSF) are observed in Alzheimer's disease (AD) patients.
- The precise mechanisms causing these POMC peptide level alterations in AD CSF remain unclear.
Observation:
- This case report examined POMC peptide processing post-mortem at pituitary and hypothalamic levels.
- Comparisons were made between an individual with Alzheimer's disease and a control subject.
Findings:
- Analysis using High-Performance Liquid Chromatography (HPLC) and Radioimmunoassay (RIA) methods was performed.
- Results suggest that impaired axonal transport and/or secretion, rather than defective synthesis, likely underlie the observed POMC peptide abnormalities in AD CSF.
Implications:
- Understanding POMC peptide dysregulation in AD offers potential insights into disease mechanisms.
- Defects in axonal transport or secretion may represent novel therapeutic targets for Alzheimer's disease.
- Further research is warranted to elucidate the role of POMC peptides in neurodegenerative disorders.